Robert S. Miller, MD, of ASCO, updates the progress of CancerLinQ and its data set, now being used by oncologists to track quality measurement and reporting.
Diana D. Jeffery, PhD, of the Defense Health Agency, discusses the need to screen for mental health comorbidities, including depression, anxiety, adjustment disorders, substance use disorders, and persistent mental illnesses, as shown in a study of breast and prostate cancer patients (Abstract 18).
Brian Weiss, MD, of Cincinnati Children’s Hospital Medical Center, discusses a program designed to eliminate errors in chemotherapy use among pediatric patients whose regimens incorporate multiple drugs and rigorous monitoring schedules (Abstract 37).
Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival analysis before and after implementing Dana-Farber Clinical Pathways for patients with stage IV non–small cell lung cancer (Abstracts 3, 52).
Julie Bryar Porter, MS, of Stanford Health Care, discusses an approach to improving patient care with physician-led quality measures from diagnosis through end of life implemented at her academic cancer center (Abstract 49).
Ethan M. Basch, MD, of The University of North Carolina at Chapel Hill, discusses programs—now rolling out at various institutions—that use direct patient reporting of symptoms as a part of quality assessment (Posters 61, 81; Abstract 218).
